{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:20:51Z","timestamp":1787988051579,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008381","name":"Institut Claudius Regaud","doi-asserted-by":"publisher","award":["Institut Claudius Regaud"],"award-info":[{"award-number":["Institut Claudius Regaud"]}],"id":[{"id":"10.13039\/501100008381","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00259-026-07992-2","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T02:41:23Z","timestamp":1782268883000},"page":"6583-6593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective study on the [18F]FDOPA PET\/CT role in the management of medullary thyroid cancer patients with high residual calcitonin level after surgery"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1395-8472","authenticated-orcid":false,"given":"Marie","family":"Terroir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Lusque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Hindi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Eberle-Pouzeratte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Verbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Decote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Grunenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slimane","family":"Zerdoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"issue":"4","key":"7992_CR1","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/1097-0142(19880215)61:4<806::aid-cncr2820610428>3","volume":"61","author":"S Schr\u00f6der","year":"1988","unstructured":"Schr\u00f6der S, B\u00f6cker W, Baisch H, B\u00fcrk CG, Arps H, Meiners I, et al. Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immunocytochemistry, and DNA content. Cancer 15 f\u00e9vr. 1988;61(4):806\u201316. https:\/\/doi.org\/10.1002\/1097-0142(19880215)61:4%3C806::aid-cncr2820610428%3E3..0.co;2-g.","journal-title":"Cancer 15 f\u00e9vr"},{"issue":"6","key":"7992_CR2","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1097\/00000658-199906000-00016","volume":"229","author":"JF Moley","year":"1999","unstructured":"Moley JF, DeBenedetti MK. Patterns of Nodal Metastases in Palpable Medullary Thyroid Carcinoma. Ann Surg juin. 1999;229(6):880. PubMed PMID: 10363903; PubMed Central PMCID: PMC1420836.","journal-title":"Ann Surg juin"},{"key":"7992_CR3","doi-asserted-by":"publisher","unstructured":"Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H Medullary Thyroid Cancer, et al. editors. Management Guidelines of the American Thyroid Association. https:\/\/www.liebertpub.com\/doi\/https:\/\/doi.org\/10.1089\/thy.2008.0403 doi:10.1089\/thy.2008.0403.","DOI":"10.1089\/thy.2008.0403"},{"issue":"1","key":"7992_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000336977","volume":"1","author":"M Schlumberger","year":"2012","unstructured":"Schlumberger M, Bastholt L, Dralle H, Jarzab B, Pacini F, Smit JWA. 2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer. Eur Thyroid J avr. 2012;1(1):5\u201314. doi:10.1159\/000336977 PubMed PMID: 24782992; PubMed Central PMCID: PMC3821456.","journal-title":"Eur Thyroid J avr"},{"issue":"6","key":"7992_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells","year":"2015","unstructured":"Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid 1 juin. 2015;25(6):567\u2013610. https:\/\/doi.org\/10.1089\/thy.2014.0335 . PubMed PMID: 25810047; PubMed Central PMCID: PMC4490627.","journal-title":"Thyroid 1 juin"},{"issue":"5","key":"7992_CR6","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1210\/jc.2002-021713","volume":"88","author":"C Scollo","year":"2003","unstructured":"Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S, et al. Rationale for Central and Bilateral Lymph Node Dissection in Sporadic and Hereditary Medullary Thyroid Cancer. J Clin Endocrinol Metab mai. 2003;88(5):2070\u20135. https:\/\/doi.org\/10.1210\/jc.2002-021713.","journal-title":"J Clin Endocrinol Metab mai"},{"issue":"1","key":"7992_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00268-001-0176-3","volume":"26","author":"A Machens","year":"2002","unstructured":"Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg janv. 2002;26(1):22\u20138. https:\/\/doi.org\/10.1007\/s00268-001-0176-3 . PubMed PMID: 11898029.","journal-title":"World J Surg janv"},{"issue":"4","key":"7992_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/bjs.4860","volume":"92","author":"P Tamagnini","year":"2005","unstructured":"Tamagnini P, Iacobone M, Sebag F, Marcy M, De Micco C, Henry JF. Lymph node involvement in macroscopic medullary thyroid carcinoma. Br J Surg 19 mars. 2005;92(4):449\u201353. https:\/\/doi.org\/10.1002\/bjs.4860.","journal-title":"Br J Surg 19 mars"},{"issue":"7","key":"7992_CR9","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.ejso.2005.03.007","volume":"31","author":"A Hamy","year":"2005","unstructured":"Hamy A, Pessaux P, Miralli\u00e9 E, Mucci-Hennekinne S, Gibelin H, Mor-Martinez C, et al. Central neck dissection in the management of sporadic medullary thyroid microcarcinoma. Eur J Surg Oncol EJSO 1 sept. 2005;31(7):774\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2005.03.007.","journal-title":"Eur J Surg Oncol EJSO 1 sept"},{"key":"7992_CR10","doi-asserted-by":"publisher","unstructured":"Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020\u2020Approved by the ESMO Guidelines Committee: February 2008, last update September 2019. This publication supersedes the previously published version\u2014Ann Oncol. 2012; 23(Suppl 7): vii110\u2013vii119. Ann Oncol. 1 d\u00e9c 2019; (12):1856\u201383. https:\/\/doi.org\/10.1093\/annonc\/mdz400","DOI":"10.1093\/annonc\/mdz400"},{"issue":"8","key":"7992_CR11","doi-asserted-by":"publisher","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","volume":"20","author":"RI Haddad","year":"2022","unstructured":"Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, et al. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw JNCCN ao\u00fbt. 2022;20(8):925\u201351. https:\/\/doi.org\/10.6004\/jnccn.2022.0040 . PubMed PMID: 35948029.","journal-title":"J Natl Compr Cancer Netw JNCCN ao\u00fbt"},{"issue":"4","key":"7992_CR12","doi-asserted-by":"publisher","first-page":"101790","DOI":"10.1016\/j.ando.2025.101790","volume":"86","author":"A Jannin","year":"2025","unstructured":"Jannin A, Escande A, Hartl D, Louvel G, Breuskin I, Borson-Chazot F, et al. ENDOCAN-TUTHYREF guidelines. Locoregional therapies for locally advanced and\/or metastatic thyroid cancer. Ann Endocrinol juill. 2025;86(4):101790. https:\/\/doi.org\/10.1016\/j.ando.2025.101790 . PubMed PMID: 40379205.","journal-title":"Ann Endocrinol juill"},{"key":"7992_CR13","doi-asserted-by":"publisher","unstructured":"The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid. carcinoma: the evidence-based refusal to endorse them by EANM due to the not evidence-based marginalization of the role of Nuclear Medicine | European Journal of Nuclear Medicine and Molecular Imaging [Internet]. [cit\u00e9 8 janv 2026]. Disponible sur: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s00259-016-3404-7","DOI":"10.1007\/s00259-016-3404-7"},{"issue":"2","key":"7992_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2174\/1874471011306020006","volume":"6","author":"K Slavikova","year":"2013","unstructured":"Slavikova K, Montravers F, Treglia G, Kunikowska J, Kaliska L, Vereb M, et al. What is currently the best radiopharmaceutical for the hybrid PET\/CT detection of recurrent medullary thyroid carcinoma? Curr Radiopharm 6 juin. 2013;6(2):96\u2013105. doi:10.2174\/1874471011306020006 PubMed PMID: 23745775.","journal-title":"Curr Radiopharm 6 juin"},{"issue":"11","key":"7992_CR15","first-page":"6647","volume":"34","author":"A Sesti","year":"2014","unstructured":"Sesti A, Mayerhoefer M, Weber M, Anner P, Wadsak W, Dudczak R, et al. Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-fluorodihydroxyphenylalanine PET. Anticancer Res nov. 2014;34(11):6647\u201354. PubMed PMID: 25368270.","journal-title":"Anticancer Res nov"},{"issue":"5","key":"7992_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1089\/thy.2009.0342","volume":"20","author":"M Luster","year":"2010","unstructured":"Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography\/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid Off J Am Thyroid Assoc mai. 2010;20(5):527\u201333. https:\/\/doi.org\/10.1089\/thy.2009.0342 . PubMed PMID: 20450432.","journal-title":"Thyroid Off J Am Thyroid Assoc mai"},{"issue":"4","key":"7992_CR17","doi-asserted-by":"publisher","first-page":"524","DOI":"10.2967\/jnumed.107","volume":"49","author":"KP Koopmans","year":"2008","unstructured":"Koopmans KP, de Groot JWB, Plukker JTM, de Vries EGE, Kema IP, Sluiter WJ, et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med Off Publ Soc Nucl Med avr. 2008;49(4):524\u201331. https:\/\/doi.org\/10.2967\/jnumed.107. .047720 PubMed PMID: 18375923.","journal-title":"J Nucl Med Off Publ Soc Nucl Med avr"},{"issue":"12","key":"7992_CR18","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.2967\/jnumed.111","volume":"52","author":"S Kauhanen","year":"2011","unstructured":"Kauhanen S, Schalin-J\u00e4ntti C, Sepp\u00e4nen M, Kajander S, Virtanen S, Schildt J, et al. Complementary roles of 18F-DOPA PET\/CT and 18F-FDG PET\/CT in medullary thyroid cancer. J Nucl Med Off Publ Soc Nucl Med d\u00e9c. 2011;52(12):1855\u201363. https:\/\/doi.org\/10.2967\/jnumed.111. .094771 PubMed PMID: 22052128.","journal-title":"J Nucl Med Off Publ Soc Nucl Med d\u00e9c"},{"issue":"1","key":"7992_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00259-019-04458-6","volume":"47","author":"L Giovanella","year":"2020","unstructured":"Giovanella L, Treglia G, Iakovou I, Mihailovic J, Verburg FA, Luster M. EANM practice guideline for PET\/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 1 janv. 2020;47(1):61\u201377. https:\/\/doi.org\/10.1007\/s00259-019-04458-6.","journal-title":"Eur J Nucl Med Mol Imaging 1 janv"},{"key":"7992_CR20","doi-asserted-by":"publisher","unstructured":"Alonzo TA, Pepe MS, Moskowitz CS. Sample size calculations for comparative studies of medical tests for detecting presence of disease. Stat Med. 30 mars. 2002;21(6):835\u201352. https:\/\/doi.org\/10.1002\/sim.1058 PubMed PMID: 11870820.","DOI":"10.1002\/sim.1058"},{"issue":"1","key":"7992_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s002590000404","volume":"28","author":"S Hoegerle","year":"2001","unstructured":"Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med janv. 2001;28(1):64\u201371. https:\/\/doi.org\/10.1007\/s002590000404.","journal-title":"Eur J Nucl Med janv"},{"key":"7992_CR22","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0351","author":"M Terroir","year":"2019","unstructured":"Terroir M, Caramella C, Borget I, Bidault S, Dromain C, El Farsaoui K, et al. Thyroid Off J Am Thyroid Assoc oct. 2019;29(10):1457\u201364. https:\/\/doi.org\/10.1089\/thy.2018.0351 . PubMed PMID: 31530235. F-18-Dopa Positron Emission Tomography\/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent\/Recurrent Disease of Medullary Thyroid Cancer Patients."},{"issue":"4","key":"7992_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.semnuclmed.2023.01.003","volume":"Endocrinology53","author":"G Treglia","year":"2023","unstructured":"Treglia G, Rufini V, Piccardo A, Imperiale A. Update on Management of Medullary Thyroid Carcinoma: Focus on Nuclear Medicine. Semin Nucl Med 1 juill. 2023;Endocrinology53(4):481\u20139. https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.01.003.","journal-title":"Semin Nucl Med 1 juill"},{"key":"7992_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s41824-022-00140-7","volume":"6","author":"MLG Kj\u00e6rulff","year":"2022","unstructured":"Kj\u00e6rulff MLG, Dias AH, Iversen P, Gormsen LC, Hjorthaug K. Early acquisition of [18F]FDOPA PET\/CT imaging in patients with recurrent or residual medullary thyroid cancer is safe\u2014and slightly better! Eur J Hybrid Imaging 25 ao\u00fbt. 2022;6:20. https:\/\/doi.org\/10.1186\/s41824-022-00140-7 . PubMed PMID: 36002696; PubMed Central PMCID: PMC9402850.","journal-title":"Eur J Hybrid Imaging 25 ao\u00fbt"},{"issue":"7","key":"7992_CR25","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/MNM.0000000000000696","volume":"38","author":"AT Golubi\u0107","year":"2017","unstructured":"Golubi\u0107 AT, Pasini Nemir E, \u017duvi\u0107 M, Mutvar A, Kusa\u010di\u0107 Kuna S, Despot M, et al. The value of 18F-DOPA PET\/CT in patients with medullary thyroid carcinoma and increased calcitonin values. Nucl Med Commun juill. 2017;38(7):636\u201341. 10. 1097\/MNM.0000000000000696 PubMed PMID: 28562377.","journal-title":"Nucl Med Commun juill"},{"issue":"2","key":"7992_CR26","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1210\/jcem.85.2","volume":"85","author":"R Cohen","year":"2000","unstructured":"Cohen R, Campos JM, Sala\u00fcn C, Heshmati HM, Kraimps JL, Proye C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d\u2019Etudes des Tumeurs a Calcitonine (GETC). J Clin Endocrinol Metab f\u00e9vr. 2000;85(2):919\u201322. https:\/\/doi.org\/10.1210\/jcem.85.2. .6556 PubMed PMID: 10690910.","journal-title":"J Clin Endocrinol Metab f\u00e9vr"},{"issue":"1","key":"7992_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11154-023-09836-y","volume":"25","author":"A Imperiale","year":"2024","unstructured":"Imperiale A, Berti V, Burgy M, Cazzato RL, Piccardo A, Treglia G. Molecular imaging and related therapeutic options for medullary thyroid carcinoma: state of the art and future opportunities. Rev Endocr Metab Disord 1 f\u00e9vr. 2024;25(1):187\u2013202. https:\/\/doi.org\/10.1007\/s11154-023-09836-y.","journal-title":"Rev Endocr Metab Disord 1 f\u00e9vr"},{"key":"7992_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40644-025-00862-4","volume":"25","author":"EC Jager","year":"2025","unstructured":"Jager EC, Brouwers AH, Metman MJH, Aykan D, de Vries LH, Lodewijk L, et al. The value of 18F-FDG PET\/CT and 18F-DOPA PET\/CT in determining the initial surgical strategy of patients with medullary thyroid cancer. Cancer Imaging 26 mars. 2025;25:41. https:\/\/doi.org\/10.1186\/s40644-025-00862-4 . PubMed PMID: 40140941; PubMed Central PMCID: PMC11938770.","journal-title":"Cancer Imaging 26 mars"},{"issue":"3","key":"7992_CR29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.eprac.2023.12.008","volume":"30","author":"ML Gild","year":"2024","unstructured":"Gild ML, Kumar S, Fuchs TL, Glover A, Sidhu S, Sywak M, et al. The Clinical Utility of Gallium-68-DOTATATE Positron Emission Tomography Scanning in Medullary Thyroid Cancer. Endocr Pract 1 mars. 2024;30(3):218\u201324. 12.008 PubMed PMID: 38103829.","journal-title":"Endocr Pract 1 mars"},{"issue":"2","key":"7992_CR30","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.amjsurg.2022.03.046","volume":"224","author":"C Pajak","year":"2022","unstructured":"Pajak C, Cadili L, Nabata K, Wiseman SM. 68Ga-DOTATATE-PET shows promise for diagnosis of recurrent or persistent medullary thyroid cancer: A systematic review. Am J Surg 1 ao\u00fbt. 2022;224(2):670\u20135. https:\/\/doi.org\/10.1016\/j.amjsurg.2022.03.046 . PubMed PMID: 35382933.","journal-title":"Am J Surg 1 ao\u00fbt"},{"issue":"1","key":"7992_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12020-022-03116-6","volume":"78","author":"SE Serfling","year":"2022","unstructured":"Serfling SE, Zhi Y, Megerle F, Fassnacht M, Buck AK, Lapa C, et al. Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma. Endocr oct. 2022;78(1):169\u201376. https:\/\/doi.org\/10.1007\/s12020-022-03116-6 . PubMed PMID: 35751778; PubMed Central PMCID: PMC9474330.","journal-title":"Endocr oct"},{"issue":"12","key":"7992_CR32","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1097\/MNM.0000000000001773","volume":"44","author":"P Li","year":"2023","unstructured":"Li P, Zhang Y, Xu T, Zhu J, Wei T, Zhao W. Sensitivities evaluation of five radiopharmaceuticals in four common medullary thyroid carcinoma metastatic sites on PET\/CT: a network meta-analysis and systematic review. Nucl Med Commun d\u00e9c. 2023;44(12):1114\u201325. .0000000000001773 PubMed PMID: 37769014; PubMed Central PMCID: PMC10631508.","journal-title":"Nucl Med Commun d\u00e9c"},{"key":"7992_CR33","doi-asserted-by":"publisher","unstructured":"Giovanella L, Tuncel M, Aghaee A, Campenni A, De Virgilio A. Petranovi\u0107 Ov\u010dari\u010dek P. Theranostics of Thyroid Cancer. Semin Nucl Med. 19 mars 2024. https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.01.011","DOI":"10.1053\/j.semnuclmed.2024.01.011"},{"key":"7992_CR34","doi-asserted-by":"publisher","first-page":"1381863","DOI":"10.3389\/fmed.2024.1381863","volume":"11","author":"A Rizzo","year":"2024","unstructured":"Rizzo A, Albano D, Dondi F, Cioffi M, Muoio B, Annunziata S, et al. Diagnostic yield of FAP-guided positron emission tomography in thyroid cancer: a systematic review. Front Med 25 mars. 2024;11:1381863. https:\/\/doi.org\/10.3389\/fmed.2024.1381863 . PubMed PMID: 38590320; PubMed Central PMCID: PMC10999586.","journal-title":"Front Med 25 mars"},{"issue":"8","key":"7992_CR35","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1089\/thy","volume":"33","author":"S Ballal","year":"2023","unstructured":"Ballal S, Yadav MP, Roesch F, Raju S, Satapathy S, Sheokand P, et al. Head-to-Head Comparison of [68Ga]Ga-DOTA.SA.FAPi and [68Ga]Ga-DOTANOC Positron Emission Tomography\/Computed Tomography Imaging for the Follow-Up Surveillance of Patients with Medullary Thyroid Cancer. Thyroid Off J Am Thyroid Assoc ao\u00fbt. 2023;33(8):974\u201382. https:\/\/doi.org\/10.1089\/thy. .2023.0008 PubMed PMID: 37171126.","journal-title":"Thyroid Off J Am Thyroid Assoc ao\u00fbt"},{"issue":"1","key":"7992_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4274\/mirt.galenos.2022.81904","volume":"32","author":"M Araz","year":"2023","unstructured":"Araz M, Soydal \u00c7, Demir \u00d6, G\u00f6kcan MK, K\u00fc\u00e7\u00fck N\u00d6. The Role of 18F-FDOPA PET\/CT in Recurrent Medullary Thyroid Cancer Patients with Elevated Serum Calcitonin Levels. Mol Imaging Radionucl Ther f\u00e9vr. 2023;32(1):1\u20137. https:\/\/doi.org\/10.4274\/mirt.galenos.2022.81904 . PubMed PMID: 36815513; PubMed Central PMCID: PMC9950688.","journal-title":"Mol Imaging Radionucl Ther f\u00e9vr"},{"issue":"2","key":"7992_CR37","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s12020-021-02930-8","volume":"75","author":"M Klain","year":"2022","unstructured":"Klain M, Hadoux J, Nappi C, Finessi M, Ambrosio R, Schlumberger M, et al. Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives. Endocr f\u00e9vr. 2022;75(2):330\u20137. https:\/\/doi.org\/10.1007\/s12020-021-02930-8 . PubMed PMID: 34748168.","journal-title":"Endocr f\u00e9vr"},{"issue":"1","key":"7992_CR38","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s12020-022-03062-3","volume":"77","author":"I Califano","year":"2022","unstructured":"Califano I, Pitoia F, Chirico R, De Salazar A, Bastianello MJ. Prospective study on the clinical relevance of 18F-DOPA positron emission tomography\/computed tomography in patients with medullary thyroid carcinoma. Endocr 1 juin. 2022;77(1):143\u201350. https:\/\/doi.org\/10.1007\/s12020-022-03062-3.","journal-title":"Endocr 1 juin"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07992-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07992-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07992-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:00:43Z","timestamp":1787986843000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07992-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["7992"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07992-2","relation":{"references":[{"id-type":"doi","id":"10.1089\/thy.2018.0351","asserted-by":"subject"}]},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Ethics approval was granted by the CPP SOOM III : South West and Overseas III ( N\u00b0 ID RCB: 2016-A01823-48).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Images are entirely unidentifable, and there are no details on individuals reported within the manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DT is a cofounder, stakeholder, and the chief medical officer (CMO) of SILON Therapeutics and reports receiving advisory board honoraria from Novartis. Others authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}